Caicun Zhou, MD, PhD, Director of the Department of Oncology at Shanghai East Hospital, Tongji University; Professor; Director of the Cancer Institute of Tongji University School of Medicine. Currently serving as President of the International Association for the Study of Lung Cancer (IASLC), Chair of the Non-Small Cell Lung Cancer Committee of the China Anti-Cancer Association, and Vice Chairman of the Shanghai Anti-Cancer Association.
He was a visiting scientist in the USA (2002). He has led or participated in over 150 multicenter lung cancer trials, including OPTIMAL, BEYOND, ALESIA, EVIDENCE, KEYNOTE-033, PAPILLON, LIBRETTO-431, CAMEL, CAMEL-Sq, GEMSTONE-302, and HARMONI-2. His laboratory research focuses on biomarkers for early lung cancer diagnosis, genomic aberrations, and prognostic/predictive markers for chemotherapy, targeted therapy, and anti-PD-1/PD-L1 immunotherapy in NSCLC.
He has published more than 330 peer-reviewed papers, including NEJM, The Lancet, Lancet Oncology, JCO, JAMA Oncology, Cancer Cell, and Nature Medicine. He has received over 20 research grants from Chinese or Shanghai government agencies, and won the 2nd Award of National Science and Technology Progress and the first Award of Shanghai Science and Technology Progress.
He is an active member of ESMO and ASCO.